Cargando…
Barriers to Oncology Biosimilars Uptake in the United States
Biosimilars are biological compounds that contain an active substance that is similar to the active substance in an already approved biologic. This commentary focuses on the barriers to the use of biosimilars in the United States.
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AlphaMed Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291332/ https://www.ncbi.nlm.nih.gov/pubmed/30049886 http://dx.doi.org/10.1634/theoncologist.2018-0066 |
_version_ | 1783380234514464768 |
---|---|
author | Nabhan, Chadi Valley, Amy Feinberg, Bruce A. |
author_facet | Nabhan, Chadi Valley, Amy Feinberg, Bruce A. |
author_sort | Nabhan, Chadi |
collection | PubMed |
description | Biosimilars are biological compounds that contain an active substance that is similar to the active substance in an already approved biologic. This commentary focuses on the barriers to the use of biosimilars in the United States. |
format | Online Article Text |
id | pubmed-6291332 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | AlphaMed Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-62913322018-12-13 Barriers to Oncology Biosimilars Uptake in the United States Nabhan, Chadi Valley, Amy Feinberg, Bruce A. Oncologist Commentary Biosimilars are biological compounds that contain an active substance that is similar to the active substance in an already approved biologic. This commentary focuses on the barriers to the use of biosimilars in the United States. AlphaMed Press 2018-07-26 2018-11 /pmc/articles/PMC6291332/ /pubmed/30049886 http://dx.doi.org/10.1634/theoncologist.2018-0066 Text en © AlphaMed Press 2018 |
spellingShingle | Commentary Nabhan, Chadi Valley, Amy Feinberg, Bruce A. Barriers to Oncology Biosimilars Uptake in the United States |
title | Barriers to Oncology Biosimilars Uptake in the United States |
title_full | Barriers to Oncology Biosimilars Uptake in the United States |
title_fullStr | Barriers to Oncology Biosimilars Uptake in the United States |
title_full_unstemmed | Barriers to Oncology Biosimilars Uptake in the United States |
title_short | Barriers to Oncology Biosimilars Uptake in the United States |
title_sort | barriers to oncology biosimilars uptake in the united states |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291332/ https://www.ncbi.nlm.nih.gov/pubmed/30049886 http://dx.doi.org/10.1634/theoncologist.2018-0066 |
work_keys_str_mv | AT nabhanchadi barrierstooncologybiosimilarsuptakeintheunitedstates AT valleyamy barrierstooncologybiosimilarsuptakeintheunitedstates AT feinbergbrucea barrierstooncologybiosimilarsuptakeintheunitedstates |